After $500M IPO, HK inno.N enters exosome drug delivery via Ilias pact PharmaTher fleshes out ketamine delivery portfolio with deal for on-body injector MIT, Brigham push oral, oil-based delivery gel toward clinic to expand pediatric toolkit SciSparc unlocks nasal cannabinoid delivery via Polyrizon pact The top 20 drugs by worldwide sales in 2021 'The Top Line' podcast: How biopharma is tackling the monkeypox outbreak, insight on nominations for our Fierce 15 list, plus this week's headlines Featured Story | By Nick Paul Taylor HK inno.N, buoyed by its $500 million IPO, has teamed up with Ilias Biologics to co-develop candidates using exosomes. The partnership brings together Ilias’ exosome platform technologies and HK inno.N’s drug development chops. read more |
| |
|---|
|
Top Stories By Nick Paul Taylor The ketamine drug delivery deals keep coming. PharmaTher is again involved in the latest agreement, teaming up with CC Biotechnology Corporation (CCBIO) to access a wearable delivery device that should be ready for the clinic early next year. read more By Nick Paul Taylor A potential new delivery format for children and other people with swallowing difficulties is closing in on the clinic. Researchers at Brigham and Women’s Hospital and the Massachusetts Institute of Technology have developed the tech to address the need for cheap, temperature-stable formats for the delivery of both water-soluble and insoluble molecules. read more By Nick Paul Taylor SciSparc has identified a new way to get its cannabinoid receptor type 2 (CB2R) agonist to targets in the brain. Having run initial studies on an intravenous formulation, the Israeli biotech is now teaming up with Polyrizon to develop an intranasal version that maintains pain-relieving concentrations of the drug. read more By Kevin Dunleavy While the global sales rankings of Big Pharma's superstar drugs naturally feature the biggest names in the business, several new meds popped up on the list this year because of the coronavirus. Pfizer's COVID-19 vaccine displaced AbbVie's Humira at the top slot, which the immunology drug had held for nearly a decade. read more By Teresa Carey This week on "The Top Line," we discuss the new monkeypox outbreak, what the treatment options are and why health officials don’t seem concerned. We also talk about Dexcom's potential megamerger with Insulet, the upcoming ASCO meeting and the week's other big headlines. Plus, we have a special announcement about the prestigious Fierce 15 competition. read more Resources Sponsored by: Catalent In this executive summary, we describe the benefits of controlled release, look at how to determine whether a drug is suitable for controlled release, review the application of PBPK modelling in controlled release formulation development and discuss how modified release products can be developed to deliver optimal patient outcomes. Sponsored by: Merit Solutions Quality operations guide your organization through regulatory compliance processes and safeguard your products, processes, and reputation. But your team is capable of so much more. Quality incident data and processes can be a driver of significant business value if shared with other stakeholders. Sponsored by: Blue Matter, strategic consultants in the life sciences Recent trends are driving big changes in Medical Affairs. This paper explores why, and what MA teams can do to stay ahead of the curve. Sponsored by: Catalent Did you know Catalent has newly expanded in-house capabilities spanning clinical and commercial scale manufacturing for DPIs, unit-dose, bi-dose and preserved multi-dose nasal sprays? Sponsored by: Catalent Orally Inhaled & Nasal Drug Delivery: A Pipeline of Opportunities Sponsored by: Catalent What are key considerations for intranasal delivery in the treatment of acute and chronic conditions? Sponsored by: PwC Don’t miss these critical considerations when evaluating your HCP interactions management program. Fierce Health Payer Summit October 12, 2022 | Free Virtual Event Fierce Biotech Cell & Gene Therapy Forum October 19, 2022 | Virtual Event Drug Development Boot Camp® 2022 November 16-17, 2022 Fierce Launch Readiness for Medical Affairs & Communications Teams Summit November 30-December 1, 2022 | Free Virtual Event | 